<DOC>
	<DOCNO>NCT00360334</DOCNO>
	<brief_summary>This phase 3 trial design compare effect twice daily exenatide plus oral antidiabetic agent ( OADs ) once-daily insulin glargine plus OADs respect glycemic control , measure hemoglobin A1c , minimum weight gain , patient uncontrolled type 2 diabetes OADs .</brief_summary>
	<brief_title>A Study Comparing Exenatide With Basal Insulin Achieving Target HbA1c With Minimum Weight Gain Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diagnosed type 2 diabetes Currently treat follow : Dual triple oral therapy stable combination dose least 3 month . HbA1c 7.5 % 10.0 % . BMI &gt; 27 . Receive chronic ( lasting longer 2 week ) systemic glucocorticoid therapy ( exclude topical inhale preparation ) receive therapy within 2 week immediately prior study . Have participate interventional medical , surgical , pharmaceutical study ( study medical surgical treatment give ) within 30 day prior entry study . Treatment follow medication : *Insulin outpatient therapy within last 3 month ; *Meglitinides , acarbose within last 3 month ; *Regular use drug directly affect gastrointestinal motility ; *Any previous ( study ) therapy exenatide glucagonlike peptide1 ( GLP1 ) analogue ; *Antiobesity agent use within last 3 month . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>insulin glargine</keyword>
	<keyword>Lilly</keyword>
	<keyword>Amylin</keyword>
</DOC>